FCF Margin % is calculated as Free Cash Flow divided by its Revenue. Avacta Group's Free Cash Flow for the
six
months ended in Dec. 2025 was £-13.28 Mil. Avacta Group's Revenue for the
six
months ended in Dec. 2025 was £0.06 Mil. Therefore, Avacta Group's FCF Margin % for the quarter that ended in Dec. 2025 was -23,305.26%.
The historical rank and industry rank for Avacta Group's FCF Margin % or its related term are showing as below:
LSE:AVCT'
s FCF Margin % Range Over the Past 10 Years
Min: -23747.79 Med: -468.99 Max: -178.09
Current: -23747.79
During the past 13 years, the highest FCF Margin % of Avacta Group was -178.09%. The lowest was -23747.79%. And the median was -468.99%.
LSE:AVCT's FCF Margin % is ranked worse than 95.72% of 959
companies
in the Biotechnology industry
Industry Median: -84.65
vs LSE:AVCT: -23747.79
Avacta Group FCF Margin % Related Terms
Avacta Group FCF Margin % Historical Data
* Premium members only.
The historical data trend for Avacta Group's FCF Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
LSE:AVCT vs VRTX, REGN, ALNY: FCF Margin % Comparison
For the Biotechnology subindustry, Avacta Group's FCF Margin %, along with its competitors' market caps and FCF Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Avacta Group FCF Margin % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Avacta Group's FCF Margin % distribution charts can be found below:
* The bar in red indicates where Avacta Group's FCF Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Avacta Group (LSE:AVCT) has a FCF Margin % of -23,305.26% as of Dec. 2025. Free cash flow margin is the ratio of total free cash flow to net sales. View historical data on Avacta Group and its competitors. According to the industry distribution chart, Avacta Group ranks #918 out of 959 companies in the Biotechnology industry, placing it in the top 95.7%.
Is Avacta Group's FCF Margin % too high?
Avacta Group's current FCF Margin % is -23,305.26%. Based on the distribution chart, Avacta Group ranks #918 out of 959 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Avacta Group has a GF Score™ of 28/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Avacta Group's FCF Margin % compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Avacta Group ranks #918 out of 959 companies for FCF Margin %. This places Avacta Group in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good FCF Margin % for a Biotechnology company?
A good FCF Margin % depends on the Biotechnology industry context. However, FCF Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high FCF Margin % mean?
A high FCF Margin % can signal that a stock is expensive relative to its fundamentals. Free cash flow margin is the ratio of total free cash flow to net sales. View historical data on Avacta Group and its competitors. Avacta Group's current FCF Margin % is -23,305.26%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Avacta Group stock overvalued right now?
Based on GuruFocus' analysis, Avacta Group (LSE:AVCT) is currently considered Significantly Overvalued. The stock's GF Value™ is £0.49, compared to a current price of £0.72 — trading 47.3% above its estimated fair value. The current FCF Margin % is -23,305.26%. Avacta Group's overall GF Score™ is 28/100 with 8 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is FCF Margin % calculated?
FCF Margin % is calculated from a company's financial statements. For Avacta Group (LSE:AVCT), the current FCF Margin % is -23,305.26% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Avacta Group (LSE:AVCT) Overvalued in 2026?
Based on GuruFocus' analysis, Avacta Group stock appears to be overvalued.
The current stock price of £0.72 is trading 47.3% above its estimated GF Value™ of £0.49.
GuruFocus considers Avacta Group to be Significantly Overvalued.
Key valuation signals for LSE:AVCT:
FCF Margin %: -23,305.26%
GF Value™: £0.49 vs. price of £0.72 (47.3% above fair value)
No single metric tells the full story. See the LSE:AVCT stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Avacta Group PLC is a clinical-stage life sciences company expanding the reach of potent cancer therapies with the pre-CISION platform. pre-CISION is a proprietary warhead delivery system based on a tumor-specific protease (fibroblast activation protein or FAP) that is designed to concentrate potent warheads in the tumor microenvironment while sparing normal tissues. The company's pipeline consists of pre-CISION peptide drug conjugates (PDC) or Affimer drug conjugates (AffDC) that leverage the tumor-specific release mechanism, providing benefits over traditional antibody drug conjugates. The firm has one reportable segment, Therapeutics, which is engaged in the development of novel cancer therapies harnessing its proprietary technology. Geographically, it derives revenue from South Korea.
28GF Score
Get the complete analysis for LSE:AVCT
FCF Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
LSE:AVCT has been successfully added to your 
